Shopping Cart 0
Cart Subtotal
USD 0

Les Laboratoires Servier SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Les Laboratoires Servier SAS (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company's portfolio of marketed products treat central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women's and male health issues, gastrointestinal diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) worldwide. The company also provides generic drugs and contract development and manufacturing services across its global network. Servier sells its products in Europe, North America, South America, Middle East, Africa and Asia. Servier headquartered in Suresnes, France.

Les Laboratoires Servier SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 16

Egis Pharma Acquires Sorbifer Rights from AstraZeneca 18

Venture Financing 19

Ilkos Therapeutics Raises USD14 Million in Seed Financing 19

Partnerships 20

Laboratorios Farmaceuticos Rovi Enters into Agreement with Biogaran 20

Les Laboratoires Servier and ScandiCure Enter into Agreement 21

ImmunoQure Enters into Agreement with Servier 22

Les Laboratoires Enters into Agreement with Treventis 23

Les Laboratoires Servier Enters into Agreement with Harvard University 24

Philochem Enters into Research Agreement with Les Laboratoires Servier 25

Servier and Transgene Enters into Research Agreement 26

Vernalis and Servier Enter into Discovery Agreement 27

Les Laboratoires Servier and Masthercell Enter into Agreement 28

Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30

Spectrum Pharma Enters into Agreement with Servier Canada 31

Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32

Vect-Horus Enters into Agreement with Servier 33

GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34

Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 35

Servier Expands Agreement with Novartis 36

Cellectis Enters Into Co-Development Agreement With Servier 37

Institut Curie Extends Research Agreement with Servier 39

Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 40

Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 41

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 42

Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 43

NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 44

Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 45

Les Labs Servier Enters Into Research Agreement With Monash Institute 47

Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 48

Licensing Agreements 49

Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 49

Servier Enters into Licensing Agreement with Numerate 50

Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 51

Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 52

Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 53

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 55

Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 56

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 57

Pfizer Enters into Licensing Agreement with Servier for UCART19 58

Servier Exercises Option for Licensing Agreement with Cellectis 59

Horizon Discovery Enters into Licensing Agreement with Servier Lab 61

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62

Taiho Pharma Enters into Licensing Agreement with Servier 63

Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 64

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 65

Celladon Enters Into Option For Licensing Agreement With Servier 67

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 68

BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 70

Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 71

Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 72

Asset Transactions 74

XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 74

Acquisition 75

Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 75

Les Laboratoires Servier SAS-Key Competitors 77

Les Laboratoires Servier SAS-Key Employees 78

Les Laboratoires Servier SAS-Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Recent Developments 83

Financial Announcements 83

Feb 22, 2018: Servier Announces 2017 annual results 83

Feb 07, 2017: Servier announces an increase in turnover for 2015-2016 85

Corporate Communications 86

Mar 06, 2018: Servier appoints a Chief Patient Officer 86

Product News 87

10/13/2017: New Formulation of ONCASPAR (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia 87

03/09/2017: Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia 88

Product Approvals 89

Feb 28, 2018: U.S. FDA Accepts Shires Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia 89

Dec 13, 2017: New Formulation of ONCASPAR (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia 90

Clinical Trials 91

Mar 08, 2018: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting 91

Dec 12, 2017: Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials 92

Nov 01, 2017: Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting 93

Other Significant Developments 94

Jul 04, 2018: Servier Netherlands mobilizes for Stem Cell Donation 94

Appendix 95

Methodology 95

About GlobalData 95

Contact Us 95

Disclaimer 95


List Of Figure

List of Figures

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Les Laboratoires Servier SAS, Deals By Therapy Area, 2012 to YTD 2018 10

Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 16

Egis Pharma Acquires Sorbifer Rights from AstraZeneca 18

Ilkos Therapeutics Raises USD14 Million in Seed Financing 19

Laboratorios Farmaceuticos Rovi Enters into Agreement with Biogaran 20

Les Laboratoires Servier and ScandiCure Enter into Agreement 21

ImmunoQure Enters into Agreement with Servier 22

Les Laboratoires Enters into Agreement with Treventis 23

Les Laboratoires Servier Enters into Agreement with Harvard University 24

Philochem Enters into Research Agreement with Les Laboratoires Servier 25

Servier and Transgene Enters into Research Agreement 26

Vernalis and Servier Enter into Discovery Agreement 27

Les Laboratoires Servier and Masthercell Enter into Agreement 28

Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30

Spectrum Pharma Enters into Agreement with Servier Canada 31

Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32

Vect-Horus Enters into Agreement with Servier 33

GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34

Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 35

Servier Expands Agreement with Novartis 36

Cellectis Enters Into Co-Development Agreement With Servier 37

Institut Curie Extends Research Agreement with Servier 39

Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 40

Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 41

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 42

Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 43

NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 44

Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 45

Les Labs Servier Enters Into Research Agreement With Monash Institute 47

Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 48

Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 49

Servier Enters into Licensing Agreement with Numerate 50

Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 51

Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 52

Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 53

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 55

Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 56

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 57

Pfizer Enters into Licensing Agreement with Servier for UCART19 58

Servier Exercises Option for Licensing Agreement with Cellectis 59

Horizon Discovery Enters into Licensing Agreement with Servier Lab 61

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62

Taiho Pharma Enters into Licensing Agreement with Servier 63

Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 64

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 65

Celladon Enters Into Option For Licensing Agreement With Servier 67

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 68

BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 70

Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 71

Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 72

XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 74

Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 75

Les Laboratoires Servier SAS, Key Competitors 77

Les Laboratoires Servier SAS, Key Employees 78

Les Laboratoires Servier SAS, Subsidiaries 79

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Les Laboratoires Servier SAS (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company's portfolio of marketed products treat central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women's and male health issues, gastrointestinal diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) worldwide. The company also provides generic drugs and contract development and manufacturing services across its global network. Servier sells its products in Europe, North America, South America, Middle East, Africa and Asia. Servier headquartered in Suresnes, France.

Les Laboratoires Servier SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 16

Egis Pharma Acquires Sorbifer Rights from AstraZeneca 18

Venture Financing 19

Ilkos Therapeutics Raises USD14 Million in Seed Financing 19

Partnerships 20

Laboratorios Farmaceuticos Rovi Enters into Agreement with Biogaran 20

Les Laboratoires Servier and ScandiCure Enter into Agreement 21

ImmunoQure Enters into Agreement with Servier 22

Les Laboratoires Enters into Agreement with Treventis 23

Les Laboratoires Servier Enters into Agreement with Harvard University 24

Philochem Enters into Research Agreement with Les Laboratoires Servier 25

Servier and Transgene Enters into Research Agreement 26

Vernalis and Servier Enter into Discovery Agreement 27

Les Laboratoires Servier and Masthercell Enter into Agreement 28

Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30

Spectrum Pharma Enters into Agreement with Servier Canada 31

Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32

Vect-Horus Enters into Agreement with Servier 33

GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34

Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 35

Servier Expands Agreement with Novartis 36

Cellectis Enters Into Co-Development Agreement With Servier 37

Institut Curie Extends Research Agreement with Servier 39

Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 40

Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 41

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 42

Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 43

NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 44

Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 45

Les Labs Servier Enters Into Research Agreement With Monash Institute 47

Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 48

Licensing Agreements 49

Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 49

Servier Enters into Licensing Agreement with Numerate 50

Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 51

Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 52

Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 53

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 55

Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 56

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 57

Pfizer Enters into Licensing Agreement with Servier for UCART19 58

Servier Exercises Option for Licensing Agreement with Cellectis 59

Horizon Discovery Enters into Licensing Agreement with Servier Lab 61

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62

Taiho Pharma Enters into Licensing Agreement with Servier 63

Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 64

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 65

Celladon Enters Into Option For Licensing Agreement With Servier 67

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 68

BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 70

Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 71

Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 72

Asset Transactions 74

XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 74

Acquisition 75

Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 75

Les Laboratoires Servier SAS-Key Competitors 77

Les Laboratoires Servier SAS-Key Employees 78

Les Laboratoires Servier SAS-Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Recent Developments 83

Financial Announcements 83

Feb 22, 2018: Servier Announces 2017 annual results 83

Feb 07, 2017: Servier announces an increase in turnover for 2015-2016 85

Corporate Communications 86

Mar 06, 2018: Servier appoints a Chief Patient Officer 86

Product News 87

10/13/2017: New Formulation of ONCASPAR (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia 87

03/09/2017: Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia 88

Product Approvals 89

Feb 28, 2018: U.S. FDA Accepts Shires Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia 89

Dec 13, 2017: New Formulation of ONCASPAR (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia 90

Clinical Trials 91

Mar 08, 2018: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting 91

Dec 12, 2017: Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials 92

Nov 01, 2017: Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting 93

Other Significant Developments 94

Jul 04, 2018: Servier Netherlands mobilizes for Stem Cell Donation 94

Appendix 95

Methodology 95

About GlobalData 95

Contact Us 95

Disclaimer 95


List Of Figure

List of Figures

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Les Laboratoires Servier SAS, Deals By Therapy Area, 2012 to YTD 2018 10

Les Laboratoires Servier SAS, Medical Devices Deals, 2012 to YTD 2018 11

Les Laboratoires Servier SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 16

Egis Pharma Acquires Sorbifer Rights from AstraZeneca 18

Ilkos Therapeutics Raises USD14 Million in Seed Financing 19

Laboratorios Farmaceuticos Rovi Enters into Agreement with Biogaran 20

Les Laboratoires Servier and ScandiCure Enter into Agreement 21

ImmunoQure Enters into Agreement with Servier 22

Les Laboratoires Enters into Agreement with Treventis 23

Les Laboratoires Servier Enters into Agreement with Harvard University 24

Philochem Enters into Research Agreement with Les Laboratoires Servier 25

Servier and Transgene Enters into Research Agreement 26

Vernalis and Servier Enter into Discovery Agreement 27

Les Laboratoires Servier and Masthercell Enter into Agreement 28

Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 29

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 30

Spectrum Pharma Enters into Agreement with Servier Canada 31

Crossbeta Biosciences Enters into Research Agreement with Servier Labs 32

Vect-Horus Enters into Agreement with Servier 33

GeNeuro Amends Co-Development Agreement with Servier for GnbAC-1 34

Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 35

Servier Expands Agreement with Novartis 36

Cellectis Enters Into Co-Development Agreement With Servier 37

Institut Curie Extends Research Agreement with Servier 39

Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 40

Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 41

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 42

Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 43

NovAliX And Servier Enter Into Drug Discovery Agreement with Les Laboratoires 44

Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 45

Les Labs Servier Enters Into Research Agreement With Monash Institute 47

Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 48

Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 49

Servier Enters into Licensing Agreement with Numerate 50

Les Laboratoires Servier Enters into Licensing Agreement with ILTOO Pharma 51

Les Laboratoires Servier Enters into Licensing Agreement with Neurochlore 52

Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 53

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 55

Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 56

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 57

Pfizer Enters into Licensing Agreement with Servier for UCART19 58

Servier Exercises Option for Licensing Agreement with Cellectis 59

Horizon Discovery Enters into Licensing Agreement with Servier Lab 61

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 62

Taiho Pharma Enters into Licensing Agreement with Servier 63

Servier Receives Rights of ITCA 650 from Intarcia Therapeutics 64

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 65

Celladon Enters Into Option For Licensing Agreement With Servier 67

MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 68

BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 70

Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 71

Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 72

XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 74

Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 75

Les Laboratoires Servier SAS, Key Competitors 77

Les Laboratoires Servier SAS, Key Employees 78

Les Laboratoires Servier SAS, Subsidiaries 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS